Adicet Bio, Inc. – NASDAQ:ACET

Add to watchlist

$0.7

-0.22

-24.37%

Market closed

Open in about 1 hour

-23.47%

month

-23.47%

quarter

-47.39%

year

Market Cap	72.02M
Enterprise value	N/A

P/E	-3.2
EV/Sales	-0.32
EV/EBITDA	0.09
Price/Sales	9.13
Price/Book	0.78
PEG ratio	-0.21
EPS	-2.95

Revenue	N/A
EBITDA	-118.76M
Income	-139.79M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-350.98%
Oper. margin	-362.61%
Gross margin	0%
EBIT margin	-362.61%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Adicet Bio, Inc. (NASDAQ:ACET): Profit margin
Jun 2023	0	-32.40M
Sep 2023	0	-49.88M
Dec 2023	12.89M	-29.48M	-228.7%
Mar 2024	0	-28.01M

Adicet Bio Financials Estimate

Q Y

Adicet Bio, Inc. (NASDAQ:ACET): Analyst Estimates
Dec 2023	12.89M	-29.48M	-228.7%
Mar 2024	0	-28.01M
Oct 2025	0	-26.09M
Dec 2025	0	-26.45M

Analysts Price target
Financials & Ratios estimates

Adicet Bio, Inc. (NASDAQ:ACET): Debt to assets
Jun 2023	277633000	38.57M	13.89%
Sep 2023	233257000	38.58M	16.54%
Dec 2023	207295000	37.12M	17.91%
Mar 2024	293095000	34.29M	11.7%

Adicet Bio, Inc. (NASDAQ:ACET): Cash Flow
Jun 2023	-24.89M	-1.50M	226K
Sep 2023	-21.23M	-906K	-59K
Dec 2023	-23.48M	-136K	76K
Mar 2024	-22.84M	-239K	110.96M

Adicet Bio alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Adicet Bio, Inc. (NASDAQ:ACET): Employee count
Aug 2023	132
Sep 2023	132
Oct 2023	132
Nov 2023	132
Dec 2023	132
Jan 2024	132
Feb 2024	132
Mar 2024	143
Apr 2024	143
May 2024	143
Jun 2024	143
Jul 2024	143

Adicet Bio
Hedge Funds Holdings Q1 2023

43.73% -56.27%

of ACET is owned by hedge funds

60 -40

hedge funds hold ACET stock

17.96M -24.07M

shares is hold by hedge funds

ACET hedge funds holdings changes

Adicet Bio, Inc. (NASDAQ:ACET): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	5500	11000
Oct 2023	5500	0
Jan 2024	6250000	0
Jun 2024	0	5900

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	5 Jun 2024	KAUFFMAN MICHAEL director	Common Stock	5,900	$1.43	$8,437
Purchase	25 Jan 2024	GORDON CARL L director, 10 percent owner: director, 10 percent owner:	Common Stock	1,841,100	$2.4	$4,418,640
Purchase	25 Jan 2024	GORDON CARL L director, 10 percent owner: director, 10 percent owner:	Common Stock	242,200	$2.4	$581,280
Purchase	25 Jan 2024	GORDON CARL L director, 10 percent owner: director, 10 percent owner:	Common Stock	1,041,700	$2.4	$2,500,080
Purchase	25 Jan 2024	ORBIMED ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	1,841,100	$2.4	$4,418,640
Purchase	25 Jan 2024	ORBIMED ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	1,041,700	$2.4	$2,500,080
Purchase	25 Jan 2024	ORBIMED ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	242,200	$2.4	$581,280
Purchase	2 Oct 2023	SCHOR CHEN director, officer: President & CEO director, officer: President & ..	Common Stock	5,500	$1.34	$7,343
Sale	29 Sep 2023	SCHOR CHEN director, officer: President & CEO director, officer: President & ..	Common Stock	5,500	$1.36	$7,480
Purchase	28 Sep 2023	SCHOR CHEN director, officer: President & CEO director, officer: President & ..	Common Stock	5,500	$1.42	$7,810

Adicet Bio
Earnings Call Transcripts

Quarter	Transcript
Q1 2019 10 Nov 2018	Q1 2019 Earnings Call Transcript
Q4 2018 28 Sep 2018	Q4 2018 Earnings Call Transcript
Q3 2018 4 May 2018	Q3 2018 Earnings Call Transcript
Q2 2018 2 Feb 2018	Q2 2018 Earnings Call Transcript

ACET earnings call transcripts

Adicet Bio
Executives

Insider	Age	Compensation
Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA (1972) Chief Executive Officer, Pres & Director	53	$750,080
Dr. Francesco Galimi M.D., Ph.D. (1968) Chief Medical Officer & Senior Vice President	57	$706,180
Dr. Aya Jakobovits Ph.D. (1953) Founder & Independent Director	72	$12,830

Adicet Bio
Latest News

Thursday, 19 December 2024
07:00	Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma	businesswire.com
Wednesday, 18 December 2024
07:00	Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer	businesswire.com
Friday, 29 November 2024
16:44	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 18 November 2024
16:00	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma	businesswire.com
Saturday, 16 November 2024
09:00	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024	businesswire.com
Friday, 1 November 2024
07:00	Adicet Bio to Participate in Upcoming Investor Conferences	businesswire.com
Thursday, 31 October 2024
17:31	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 30 September 2024
17:08	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
16:30	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference	businesswire.com
07:00	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases	businesswire.com
Thursday, 19 September 2024
07:00	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue	businesswire.com
Friday, 30 August 2024
19:13	UL Solutions Warns of Potentially Hazardous Communications Cable	businesswire.com
17:44	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Tuesday, 9 July 2024
10:56	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag	zacks.com
Tuesday, 2 July 2024
17:05	3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns	investorplace.com
Monday, 24 June 2024
07:00	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma	businesswire.com
Monday, 10 June 2024
19:22	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024	investorplace.com
Wednesday, 5 June 2024
07:00	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis	businesswire.com
Friday, 31 May 2024
17:41	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Wednesday, 29 May 2024
07:00	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference	businesswire.com
Tuesday, 14 May 2024
16:01	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates	businesswire.com
10:00	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress	businesswire.com
Tuesday, 7 May 2024
07:00	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference	businesswire.com
Tuesday, 30 April 2024
17:10	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 22 April 2024
16:30	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	businesswire.com
Monday, 8 April 2024
07:00	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference	businesswire.com
Thursday, 4 April 2024
09:41	Why Adicet Bio (ACET) Stock Might be a Great Pick	Zacks Investment Research
Monday, 1 April 2024
10:46	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?	Zacks Investment Research
Thursday, 28 March 2024
14:28	The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness	InvestorPlace
Friday, 22 March 2024
10:36	Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 9 Jan 2024

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch
Seeking Alpha 2 Sep 2023

CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch
Seeking Alpha 7 Feb 2023

Adicet Bio: Searching For Upside In Cell Therapeutics
Seeking Alpha 22 Jul 2022

Adicet Bio: A First Take
Seeking Alpha 30 Jun 2022

Healthcare Sector Stock Performance Continues To Improve
Seeking Alpha 9 Feb 2022

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Seeking Alpha 25 Apr 2021

Week 17 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Frequently Asked Questions (FAQ)

What's the price of Adicet Bio stock today?

One share of Adicet Bio stock can currently be purchased for approximately $0.7.
When is Adicet Bio's next earnings date?

Unfortunately, Adicet Bio's (ACET) next earnings date is currently unknown.
Does Adicet Bio pay dividends?

No, Adicet Bio does not pay dividends.
How much money does Adicet Bio make?

Adicet Bio has a market capitalization of 72.02M.
What is Adicet Bio's stock symbol?

Adicet Bio, Inc. is traded on the NASDAQ under the ticker symbol "ACET".
What is Adicet Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Adicet Bio?

Shares of Adicet Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Adicet Bio's key executives?
Adicet Bio's management team includes the following people:
- Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA Chief Executive Officer, Pres & Director(age: 53, pay: $750,080)
- Dr. Francesco Galimi M.D., Ph.D. Chief Medical Officer & Senior Vice President(age: 57, pay: $706,180)
- Dr. Aya Jakobovits Ph.D. Founder & Independent Director(age: 72, pay: $12,830)
Is Adicet Bio founder-led company?

Yes, Adicet Bio is a company led by its founder Dr. Aya Jakobovits Ph.D..
How many employees does Adicet Bio have?

As Jul 2024, Adicet Bio employs 143 workers.
When Adicet Bio went public?

Adicet Bio, Inc. is publicly traded company for more then 7 years since IPO on 26 Jan 2018.
What is Adicet Bio's official website?

The official website for Adicet Bio is adicetbio.com.
Where are Adicet Bio's headquarters?

Adicet Bio is headquartered at 200 Clarendon Street, Boston, MA.
How can i contact Adicet Bio?

Adicet Bio's mailing address is 200 Clarendon Street, Boston, MA and company can be reached via phone at +65 05039095.

Adicet Bio, Inc.

adicetbio.com

Exchange:

NASDAQ

Full time employees:

143

Industry:

Biotechnology

Sector:

Healthcare

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

+65 05039095

200 Clarendon Street
Boston, MA 02116

CIK: 0001720580
ISIN: US0070021086
CUSIP: 007002108